Navigation Links
GranuFlo Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal GranuFlo Recall Litigation
Date:11/4/2013

New York, NY (PRWEB) November 04, 2013

The federal court overseeing hundreds of GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) filed in the wake of last year’s recall of GranuFlo and NaturaLyte dialysis drugs held a Status Conference on November 1, 2013, Bernstein Liebhard LLP reports. According to court documents filed in U.S. District Court, District of Massachusetts, the Court took up a number of motions pending in the litigation. In a Notice filed on October 31st, attorneys representing Fresenius Medical Care reported that some of those motions were filed by dialysis lawsuit plaintiffs seeking to have their cases remanded back to the state courts where they were originally filed. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“Since the GranuFlo recall, our firm has heard from dialysis patients on a regular basis who suffered life-threatening heart problems, allegedly due to GranuFlo or NaturaLyte. We are pleased to see the GranuFlo litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free GranuFlo lawsuit evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the administration of GranuFlo and NaturaLyte during dialysis treatments.

GranuFlo Lawsuits
Court records indicate that at least 312 dialysis lawsuits have been filed in the District of Massachusetts on behalf of individuals who were allegedly harmed by GranuFlo or NaturaLyte. Additional claims involving similar allegations are also pending at the state level in Massachusetts’ Middlesex County Superior Court. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O). All of the GranuFlo lawsuits involve similar allegations that Fresenius Medical Care failed to provide adequate warnings regarding the use of GranuFlo and NaturaLyte, and continued to aggressively market both products after their risks became apparent in order to protect their market share.

GranuFlo and NaturaLyte are used during dialysis to remove acid from the blood. In March 2012, an Urgent Product Notification issued by Fresenius Medical Care warned of sudden, life-threatening heart problems that could occur due to inappropriate dosing of the drugs. The New York Times reported in June 2012 that many doctors were unaware that, compared to rival products, GranuFlo and NaturaLyte contained more of an ingredient the body converts to bicarbonate. As such, certain dosages could result in dangerously elevated levels of bicarbonate in the blood, resulting in metabolic alkalosis, a condition that can cause deadly heart problems in dialysis patients.*

In June 2012, the U.S. Food & Drug Administration (FDA) granted Class I recall status to Fresenius Medical Care’s Urgent Product Notification, which indicates that a medical product poses a significant risk of serious injury or death. According to The Times, the agency also began investigating Fresenius Medical Care shortly after learning of a memo the company had issued in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte. The agency is trying to determine if Fresenius violated federal regulations, as none of its customer clinics outside of the Fresenius network were issued a similar warning about GranuFlo and NaturaLyte at that time.

Individuals treated with GranuFlo or NaturaLyte, or their families, may be entitled to file a dialysis lawsuit against Fresenius Medical Care if they or their loved one suffered cardiac arrest, heart attack, stroke, or sudden cardiac death, within 72 hours of a dialysis treatment with one of these drugs. Learn More about the GranuFlo recall at Bernstein Liebhard LLP’s website. For additional information, and to arrange for a free case review, please call 800-511-5092.

*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.thegranuflolawsuit.com/

Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/dialysis-lawsuit/prweb11299449.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New GranuFlo Lawsuit Website from Bernstein Liebhard LLP Provides Vital Dialysis Recall Information, Instructions on Filing a Claim
2. Baron and Budd GranuFlo Lawsuit Lawyers Reviewing Claims Made By Dialysis Patients Allegedly Injured by GranuFlo
3. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Conference in Federal GranuFlo Recall Litigation
4. GranuFlo Lawsuits Mount, as Bernstein Liebhard LLP Notes New Consolidated Litigation for GranuFlo Recall Claims Filed in Massachusetts State Court
5. GranuFlo Lawsuit News: Bernstein Liebhard LLP Comments on Fresenius FDA Warning Letter, as GranuFlo Recall Claims Mount
6. GranuFlo Lawsuits News: Calif. Lawsuit Alleges Drug Maker Hid Serious Health Risks, Rottenstein Law Group LLP Reports
7. 201 Actions Pending in the Granuflo Multidistrict Litigation: Now, AttorneyOne Can Provide Advice
8. GranuFlo Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Conference in Federal GranuFlo Recall Litigation
9. NaturaLyte and GranuFlo Lawsuits Are Heating Up
10. New Fresenius NaturaLyte, GranuFlo Dialysis Heart Attack Lawsuit Allegations Update: Resource4thePeople Reports Important Hearing Is Scheduled in Fresenius Multidistrict Litigation
11. Rottenstein Law Group LLP Announces Launch of GranuFlo Lawsuit Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... MA (PRWEB) , ... February 11, 2016 , ... The ... overpaying for IT services, what questions to ask your IT consultant before signing a ... access to your computer network. , “With companies relying heavily on e-mail and technology, ...
(Date:2/10/2016)... ... February 10, 2016 , ... President Obama’s ... Advantage organizations to deliver medical services via telehealth, estimated to generate more than ... for such language for many years. Although there is more to be ...
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team ... raise awareness of Nestlé KITKAT as the first global confectionery brand sourced from 100% ... farmers and the quality of their product, through activities that focus on better farming, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Western ... dental health services to the developmentally disabled in the Coachella Valley. , The ... a new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City Health ... (VRI). , For nearly 23 years, Heart City Health Center has provided the ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  The ... Nursing received an in-kind gift from ... a VeinViewer® Vision vein finder for the ... help students as they learn how to ... technology with traditional technique. ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 /PRNewswire/ ... of Pro Medicus Ltd. (ASX: PME), has announced that ... University of Florida (UF) have selected the Visage ... diagnostic viewer of the Emergent/Critical Care Imaging SIMulation ... Wisdom in Diagnostic Imaging Program (WIDI), a multi-faceted ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
Breaking Medicine Technology: